AVITA MEDICAL WKN: A0Q40S ISIN: AU000000AVH4 Kürzel: AVMXF Forum: Aktien Thema: Hauptdiskussion
1,915 EUR
+20,44 %+0,325
31. Oct, 23:00:21 Uhr,
L&S Exchange
Kommentare 605
Summer.76,
18.10.2023 17:08 Uhr
0
AVITA Medical Announces Preliminary Third Quarter 2023 Financial Highlights and Secures up to $90 million of Non-Dilutive Debt Financing with OrbiMed to Support Growth Initiatives
https://finance.yahoo.com/news/avita-medical-announces-preliminary-third-130000951.html
Summer.76,
02.10.2023 8:31 Uhr
0
https://hotcopper.com.au/threads/ann-form-8-k.7611749/
AVITA Medical, Inc. (the "Company") will lodge the following Form 8-K with the United
states Securities and Exchange Commission (the "SEC") before the market opens on 2
October 2023, being 2 October 2023 AEDT and date of lodgement on the Australian Securities
Exchange. The Form 8-K describes a recent U.S. Food and Drug Administration (the "FDA")
letter to the Company that is requesting additional information on its premarket approval
supplement application for its latest device, RECELL GO. This places the application file on
hold for approximately 4 to 6 months while the Company addresses the FDA's questions.
Summer.76,
27.09.2023 15:47 Uhr
0
https://beststocks.com/analysts-express-growing-positive-sentiment-t/
Summer.76,
26.09.2023 6:17 Uhr
0
AVITA Medical Receives Best Product Award at the American Association for the Surgery of Trauma
https://finance.yahoo.com/news/avita-medical-receives-best-product-120000477.html
Summer.76,
10.08.2023 22:27 Uhr
0
AVITA Medical GAAP EPS of -$0.41 misses by $0.10, revenue of $11.75M beats by $0.18M
https://seekingalpha.com/news/4001261-avita-medical-gaap-eps-of-0_41-misses-0_10-revenue-of-11_75m-beats-0_18m
• AVITA Medical press release (NASDAQ:RCEL): Q2 GAAP EPS of -$0.41 misses by $0.10.
• Revenue of $11.75M (+40.9% Y/Y) beats by $0.18M.
• Financial Guidance
• Commercial revenue for the third quarter 2023 is expected to be in the range of $13 to $14 million
• Raising commercial revenue for the full year 2023 from $49 to $51 million to an expected range of $51 to $53 million
• Gross margin for the full year 2023 expected to be in the range of 83% to 85%
Summer.76,
10.08.2023 22:04 Uhr
0
AVITA Medical Reports Second Quarter Financial Results
https://www.globenewswire.com/news-release/2023/08/10/2723105/0/en/AVITA-Medical-Reports-Second-Quarter-Financial-Results.html
Summer.76,
28.07.2023 17:01 Uhr
0
https://beststocks.com/avita-medical-receives-positive-outlook-and-i/
Summer.76,
20.07.2023 19:10 Uhr
0
AVITA's Balancing Act: RECELL System's Promise Amid Market Uncertainties
https://seekingalpha.com/article/4618423-avitas-balancing-act-recell-systems-promise-amid-market-uncertainties
Summer.76,
30.06.2023 5:37 Uhr
0
AVITA Medical Submits FDA PMA Supplement for RECELL GO
https://finance.yahoo.com/news/avita-medical-submits-fda-pma-222100572.html
Summer.76,
28.06.2023 17:47 Uhr
0
Skin Grafts Disruption: Avita Medical's Regenerative Medicine System Poised to Disrupt Traditional Skin Grafts, Says Analyst
https://markets.businessinsider.com/news/stocks/skin-grafts-disruption-avita-medical-s-regenerative-medicine-system-poised-to-disrupt-traditional-skin-grafts-says-analyst-1032413234
Cantor Fitzgerald has initiated coverage on Avita Medical Inc (NASDAQ:RCEL) at an Overweight rating and a price target of $23.
The analyst notes that the company's RECELL system will disrupt traditional split-thickness skin grafts, requiring 97.5% less donor skin when used alone in second-degree burns and 32.0% less donor skin when used with autograft for third-degree burns.
It requires 56% and 60% fewer autograft procedures for pediatric and adult patients with >60% TBSA (total body surface area), respectively, a shorter length of hospital stay, and reduced scarring and pain. ...
Summer.76,
26.06.2023 14:38 Uhr
0
AVITA Medical Rejoins the Russell 3000 Index
https://www.globenewswire.com/news-release/2023/06/26/2694404/0/en/AVITA-Medical-Rejoins-the-Russell-3000-Index.html
Summer.76,
19.06.2023 5:06 Uhr
0
AVITA scores US FDA approval for vitiligo treatment
https://www.businessnewsaustralia.com/articles/avita-scores-us-fda-approval-for-vitiligo-treatment.html
Summer.76,
19.06.2023 5:05 Uhr
0
AVITA Medical Announces FDA Approval of RECELL for Skin Repigmentation in Vitiligo Patients
https://www.globenewswire.com/news-release/2023/06/16/2689906/0/en/AVITA-Medical-Announces-FDA-Approval-of-RECELL-for-Skin-Repigmentation-in-Vitiligo-Patients.html
M
MaxundMoritz,
08.06.2023 8:04 Uhr
0
👍 hört sich schon mal gut an
Summer.76,
08.06.2023 5:05 Uhr
1
AVITA Medical Announces FDA Approval of RECELL for Treatment of Full-Thickness Skin Defects
https://www.businessupturn.com/brand-post/avita-medical-announces-fda-approval-of-recell-for-treatment-of-full-thickness-skin-defects/
Meistdiskutiert
|
Thema | ||
---|---|---|---|
1 | BED BATH & BEYOND Hauptdiskussion | ±0,00 % | |
2 | Super Micro Computer Hauptdiskussion | -14,61 % | |
3 | Wirtschaftsdaten und Aktien Chat | -0,74 % | |
4 | Neues DeFi Technologies Forum | -5,48 % | |
5 | PAYPAL Hauptdiskussion | +1,37 % | |
6 | CYTOMX THERAPEUTICS INC. Hauptdiskussion | +0,29 % | |
7 | TESLA MOTORS Hauptdiskussion | -2,81 % | |
8 | BALLARD POWER Hauptdiskussion | ±0,00 % | |
9 | Lilium Aktie | -8,72 % | |
10 | Phunware aktuel zur Wahl | -3,89 % | Alle Diskussionen |
Aktien
|
Thema | ||
---|---|---|---|
1 | BED BATH & BEYOND Hauptdiskussion | ±0,00 % | |
2 | Super Micro Computer Hauptdiskussion | -14,61 % | |
3 | Wirtschaftsdaten und Aktien Chat | -0,74 % | |
4 | Neues DeFi Technologies Forum | -5,48 % | |
5 | PAYPAL Hauptdiskussion | +1,37 % | |
6 | CYTOMX THERAPEUTICS INC. Hauptdiskussion | +0,29 % | |
7 | BALLARD POWER Hauptdiskussion | ±0,00 % | |
8 | TESLA MOTORS Hauptdiskussion | -2,78 % | |
9 | Lilium Aktie | -8,72 % | |
10 | Smartbroker Holding AG Hauptdiskussion | -3,66 % | Alle Diskussionen |